Business Context and Reporting Period
Company: Humacyte, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: November 10, 2022
Reporting Period: Fiscal Third Quarter ended September 30, 2022
Context: This filing serves to announce the issuance of a press release regarding the company's financial results for the specified quarter. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing a press release (Exhibit 99.1) but does not contain specific financial data tables or narrative figures within the body of this document.
- Revenue: Not provided in this filing text.
- Profit/Loss: Not provided in this filing text.
- Cash Flow: Not provided in this filing text.
- Margins: Not provided in this filing text.
- Debt and Liquidity: Not provided in this filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release but does not include the content of management's commentary, guidance, or outlook within this specific text.
Risks and Contingencies: No specific risks or contingencies are detailed in the body of this Form 8-K.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 10, 2022) for actual revenue, net loss, and cash position figures.
- Verify the company's status as an Emerging Growth Company (indicated as "x" in the filing) and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbols for Common Stock (HUMA) and Redeemable Warrants (HUMAW) on The Nasdaq Stock Market LLC.
- Check the exercise price of the warrants, which is stated as $11.50 per share.